Collegium Pharmaceutical, Inc. (COLL)
| Market Cap | 1.06B |
| Revenue (ttm) | 780.57M |
| Net Income (ttm) | 62.87M |
| Shares Out | 32.41M |
| EPS (ttm) | 1.73 |
| PE Ratio | 18.91 |
| Forward PE | 4.53 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 474,480 |
| Open | 33.08 |
| Previous Close | 32.78 |
| Day's Range | 32.54 - 33.44 |
| 52-Week Range | 26.16 - 50.79 |
| Beta | 0.77 |
| Analysts | Strong Buy |
| Price Target | 51.40 (+56.66%) |
| Earnings Date | May 7, 2026 |
About COLL
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company’s portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxyco... [Read more]
Financial Performance
In 2025, Collegium Pharmaceutical's revenue was $780.57 million, an increase of 23.62% compared to the previous year's $631.45 million. Earnings were $62.87 million, a decrease of -9.13%.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for COLL stock is "Strong Buy." The 12-month stock price target is $51.4, which is an increase of 56.66% from the latest price.
News
Collegium to Report First Quarter 2026 Financial Results on May 7, 2026
STOUGHTON, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report first quarter 2026 financial results before the market opens on T...
Collegium Pharmaceutical Transcript: 25th Annual Needham Virtual Healthcare Conference
2026 guidance projects steady revenue and EBITDA growth, led by strong ADHD franchise expansion and the AZSTARYS acquisition, which is expected to be immediately accretive. Pain portfolio remains stable despite generic pressures, and capital strategy balances growth investments with financial discipline.
Collegium to Participate in Upcoming Investor Conferences
STOUGHTON, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in the following investor conferences: 25th Annu...
Collegium Pharmaceutical Transcript: M&A announcement
The acquisition of AZSTARYS adds a differentiated ADHD medicine, extends exclusivity to 2037, and is expected to be immediately accretive to EBITDA. Operational synergies and a larger sales force are anticipated to drive growth and cost savings, with the deal closing expected in Q2 2026.
Collegium to Acquire AZSTARYS® from Corium Therapeutics, Strengthening Position in ADHD and Accelerating Growth Trajectory
– Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium's Existing ADHD Portfolio – – Enables Greater Impact Across ADHD Patient Communities – – AZSTARYS...
Collegium Pharmaceutical Transcript: Barclays 28th Annual Global Healthcare Conference
Record-breaking 2025 performance was driven by JORNAY PM's rapid growth and a stable pain portfolio. 2026 guidance projects continued strong demand for JORNAY PM and stable pain franchise revenues, supported by disciplined capital allocation and a robust balance sheet.
Collegium to Present New Real-World Data at PainConnect 2026
STOUGHTON, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will present two posters featuring real-world data from its portfolio of different...
Collegium Pharmaceutical Earnings Call Transcript: Q4 2025
Record 2025 results with 24% revenue and 15% adjusted EBITDA growth, driven by strong performance in both ADHD and pain portfolios. 2026 guidance anticipates continued double-digit growth for Jornay PM and stable pain revenues, supported by strategic capital deployment and a new $980M credit facility.
Collegium Reports Fourth Quarter and Full-Year 2025 Financial Results
– Generated Quarterly Net Revenues of $205.4 Million, Up 13% Year-over-Year, and Record Full-Year Net Revenues of $780.6 Million, Up 24% Year-over-Year –
Collegium to Present Four Real-World Data Posters at APSARD 2026 Annual Conference
STOUGHTON, Mass., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will have four poster presentations highlighting real-world data from its ADHD prod...
Collegium Provides 2026 Financial Guidance and Business Update
– Product Revenues, Net Expected in the Range of $805 Million to $825 Million – – Jornay PM ® Net Revenue Expected in the Range of $190 Million to $200 Million – – Adjusted EBITDA* Expected in the Ran...
Collegium Announces the Closing of $980 Million Syndicated Credit Facility
STOUGHTON, Mass., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), today announced the closing of its inaugural syndicated credit facility.
Collegium Pharmaceutical Transcript: Piper Sandler 37th Annual Healthcare Conference
Jornay PM continues to drive growth with strong prescription gains and expanded sales coverage, supported by improved gross-to-net and favorable market dynamics. The pain franchise maintains exclusivity with limited generic threats, while capital deployment focuses on business development, shareholder returns, and debt reduction.
Collegium Pharmaceutical Transcript: Jefferies London Healthcare Conference 2025
Significant revenue and EBITDA growth is driven by differentiated pain and ADHD products, with Jornay PM as a key growth driver. Strategic investments in sales and marketing, durable pain portfolio revenues, and disciplined capital deployment support a strong outlook.
Collegium Pharmaceutical Earnings Call Transcript: Q3 2025
Record Q3 revenue and EBITDA were driven by strong growth in both ADHD and pain portfolios, prompting raised 2025 guidance. Jornay PM prescriptions and market share surged, while capital deployment remained disciplined with share repurchases and debt repayment.
Collegium Reports Third Quarter 2025 Financial Results; Raises 2025 Guidance
– Generated Record Quarterly Net Revenue of $209.4 Million, Up 31% Year-over-Year – – Generated Record Quarterly Jornay PM ® Net Revenue of $41.8 Million; Grew Prescriptions by 20% Year-over-Year – – ...
Knight Therapeutics Announces Launch of JORNAY PM™ in Canada
MONTREAL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of JORNAY PM™ (methylph...
Collegium to Report Third Quarter 2025 Financial Results on November 6, 2025
STOUGHTON, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report third quarter 2025 financial results before the market opens on Th...
Collegium Announces Poster Presentations at the American Academy of Child & Adolescent Psychiatry and Neuroscience Education Institute Conferences
STOUGHTON, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will have poster presentations highlighting real-world data from its differentiated...
Collegium to Celebrate 10-Year Anniversary with Nasdaq Opening Bell Ringing
STOUGHTON, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management team will ring the Nasdaq opening bell on October 14, 2025 at 9:30...
Collegium Pharmaceutical Transcript: H.C. Wainwright 27th Annual Global Investment Conference
Strong net sales growth is driven by differentiated pain and ADHD products, with JORNAY PM gaining market share through expanded sales efforts and targeted DTC campaigns. The pain portfolio remains resilient, and disciplined capital allocation supports ongoing acquisitions, share repurchases, and debt reduction.
Collegium Pharmaceutical Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
Management highlighted strong growth in ADHD and pain portfolios, with raised revenue guidance and robust commercial execution. Strategic investments in sales force and awareness are expected to drive further gains, while the pain franchise's durability and cash flow support ongoing business development and shareholder returns.
Collegium to Present Nine Real-World Data Posters at PAINWeek 2025 Annual Meeting
STOUGHTON, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will present nine posters showcasing real-world data from its differentiated pain p...
Collegium Pharmaceutical Earnings Call Transcript: Q2 2025
Record Q2 revenue and adjusted EBITDA growth were driven by JORNAY and the pain portfolio, prompting raised 2025 guidance. JORNAY prescriptions surged 23% year-over-year, with strong adult segment growth and expanded sales force support. Cash flow and capital deployment remain robust.
Collegium Reports Second Quarter 2025 Financial Results; Raises 2025 Outlook
– Generated Record Quarterly Net Revenue of $188.0 Million, Up 29% Year-over-Year – – Generated Record Quarterly Jornay PM ® Net Revenue of $32.6 Million and Grew Prescriptions by 23% Year-over-Year –...